Amgen (AMGN)

Amgen’s new osteoporosis drug, Denosumab, which is scheduled for FDA approval on October 19, may now be delayed.
Denosumab is viewed by some as the most significant biotech launch in years. Analysts are now expecting a possible 3-month delay in approval because the FDA may want more time to study the drug’s safety record.

Oct 15 · 11:17:00 AM · Source: Easy Bourse
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto